PDCD1 and acute myeloid leukemia: Another phase II study examined the effect of anti-PD-1 therapy after autologous HSCT in post-remission, non-favorable risk AML patients as an alternative to allogeneic HSCT, given the psychosocial challenges that come with the latter (e.g., inability to find a matched donor).